GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

Virus Diseases

Phase 2

A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults

CompletedNCT02485301

GlaxoSmithKlineVirus Diseases

Start: 2015-07-15End: 2016-12-23Updated: 2018-01-04

A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children

CompletedNCT02548078

GlaxoSmithKlineVirus Diseases

Start: 2015-11-09End: 2017-05-15Updated: 2018-05-03

Related Papers

Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.

2020-03-1940 citations

Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.

2020-03-1932 citations